Addendum: Brolucizumab (Beovu) for Age-Related Macular Degeneration

Date: March 9, 2020
Issue #: 
1593Summary: 
We reviewed brolucizumab (Beovu– Novartis) for treatment
of neovascular (wet) age-related macular degeneration in our
February 10 issue. On February 23, the American Society of
Retina Specialists reported that 14 patients who received the
drug have developed retinal vasculitis, a potentially vision-threatening
complication.

Source: The Medical Letter - February 28, 2020 Category: Drugs & Pharmacology Authors: admin Tags: Age-related macular degeneration Beovu brolucizumab Drug Safety Source Type: research